Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Nanoerythropoietin is 10-times more effective than regular erythropoietin in neuroprotection in a neonatal rat model of hypoxia and ischemia.

Authors: Chen, H  Spagnoli, F  Burris, M  Rolland, WB  Fajilan, A  Dou, H  Tang, J  Zhang, JH 
Citation: Chen H, etal., Stroke. 2012 Mar;43(3):884-7. doi: 10.1161/STROKEAHA.111.637090. Epub 2011 Dec 8.
Pubmed: (View Article at PubMed) PMID:22156696
DOI: Full-text: DOI:10.1161/STROKEAHA.111.637090

BACKGROUND AND PURPOSE: Erythropoietin (EPO) has been demonstrated to possess significant neuroprotective effects in stroke. We determined if the nano-drug form of human recombinant EPO (PLGA-EPO nanoparticles [PLGA-EPO-NP]) can enhance neuroprotection at lower dosages versus human recombinant EPO (r-EPO). METHODS: Established neonatal rat model of unilateral ischemic stroke was used to compare r-EPO, PLGA-EPO-NP and phosphate-buffered saline, given by daily intraperitoneal injections, followed by infarction volume and Rotarod Performance Test assessment. RESULTS: PLGA-EPO-NP significantly reduced infarction volumes 72 hours after injury compared with the same concentrations of r-EPO. Functional deficits were significantly reduced by 300 U/kg PLGA-EPO-NP versus controls, with deficit attenuation apparent at significantly lower dosages of PLGA-EPO-NP versus r-EPO. CONCLUSIONS: PLGA-EPO-NP is neuroprotective and beneficial against deficits after brain ischemia, at significantly reduced dosages versus r-EPO.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 10401072
Created: 2015-09-23
Species: All species
Last Modified: 2015-09-23
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.